Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 1.77 million shares were traded. HUMA stock price reached its highest trading level at $1.46 during the session, while it also had its lowest trading level at $1.41.
Ratios:
Our goal is to gain a better understanding of HUMA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.93 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 20.66 whereas as Long-Term Debt/Eq ratio is at 19.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on August 27, 2025, initiated with a Overweight rating and assigned the stock a target price of $3.50.
H.C. Wainwright reiterated its Buy rating for the stock on December 20, 2024, while the target price for the stock was revised from $12 to $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’25 when Dougan Brady W sold 1,100,000 shares for $1.63 per share. The transaction valued at 1,793,000 led to the insider holds 591,685 shares of the business.
Dougan Brady W sold 549,360 shares of HUMA for $1,005,329 on Aug 18 ’25. The Director now owns 1,691,685 shares after completing the transaction at $1.83 per share. On Aug 20 ’25, another insider, Dougan Brady W, who serves as the Director of the company, sold 591,685 shares for $1.58 each. As a result, the insider received 934,862 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 231223120 and an Enterprise Value of 277155360. For the stock, the TTM Price-to-Sale (P/S) ratio is 281.98 while its Price-to-Book (P/B) ratio in mrq is 56.33. Its current Enterprise Value per Revenue stands at 338.821 whereas that against EBITDA is -2.667.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.88, which has changed by -0.7229601 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $6.77, while it has fallen to a 52-week low of $1.15. The 50-Day Moving Average of the stock is -30.45%, while the 200-Day Moving Average is calculated to be -49.95%.
Shares Statistics:
The stock has traded on average 4.45M shares per day over the past 3-months and 3154090 shares per day over the last 10 days, according to various share statistics. A total of 156.34M shares are outstanding, with a floating share count of 131.13M. Insiders hold about 17.20% of the company’s shares, while institutions hold 36.78% stake in the company. Shares short for HUMA as of 1755216000 were 34251609 with a Short Ratio of 7.70, compared to 1752537600 on 32720780. Therefore, it implies a Short% of Shares Outstanding of 34251609 and a Short% of Float of 24.82.
Earnings Estimates
A comprehensive evaluation of Humacyte Inc (HUMA) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.23 and -$0.59 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.23, with 4.0 analysts recommending between $0.77 and -$0.67.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $2.13M. There is a high estimate of $3.2M for the next quarter, whereas the lowest estimate is $1.34M.
Based on 6 analysts’ estimates, the company’s revenue will be $64.36M in the next fiscal year. The high estimate is $237.19M and the low estimate is $15.33M.
